1. Home
  2. MESO vs WMK Comparison

MESO vs WMK Comparison

Compare MESO & WMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • WMK
  • Stock Information
  • Founded
  • MESO 2004
  • WMK 1912
  • Country
  • MESO Australia
  • WMK United States
  • Employees
  • MESO N/A
  • WMK N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • WMK Food Chains
  • Sector
  • MESO Health Care
  • WMK Consumer Staples
  • Exchange
  • MESO Nasdaq
  • WMK Nasdaq
  • Market Cap
  • MESO 2.0B
  • WMK 1.8B
  • IPO Year
  • MESO N/A
  • WMK N/A
  • Fundamental
  • Price
  • MESO $16.37
  • WMK $71.56
  • Analyst Decision
  • MESO Buy
  • WMK
  • Analyst Count
  • MESO 4
  • WMK 0
  • Target Price
  • MESO $18.00
  • WMK N/A
  • AVG Volume (30 Days)
  • MESO 255.7K
  • WMK 79.9K
  • Earning Date
  • MESO 03-04-2025
  • WMK 03-04-2025
  • Dividend Yield
  • MESO N/A
  • WMK 1.90%
  • EPS Growth
  • MESO N/A
  • WMK N/A
  • EPS
  • MESO N/A
  • WMK 3.56
  • Revenue
  • MESO $5,902,000.00
  • WMK $4,759,577,000.00
  • Revenue This Year
  • MESO $140.44
  • WMK N/A
  • Revenue Next Year
  • MESO $318.31
  • WMK N/A
  • P/E Ratio
  • MESO N/A
  • WMK $20.10
  • Revenue Growth
  • MESO N/A
  • WMK N/A
  • 52 Week Low
  • MESO $1.91
  • WMK $59.70
  • 52 Week High
  • MESO $22.00
  • WMK $76.62
  • Technical
  • Relative Strength Index (RSI)
  • MESO 39.05
  • WMK 59.73
  • Support Level
  • MESO $18.00
  • WMK $70.08
  • Resistance Level
  • MESO $18.49
  • WMK $72.82
  • Average True Range (ATR)
  • MESO 0.82
  • WMK 1.51
  • MACD
  • MESO -0.41
  • WMK 0.21
  • Stochastic Oscillator
  • MESO 1.75
  • WMK 78.72

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About WMK Weis Markets Inc.

Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products consist of center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.

Share on Social Networks: